EGFR and interstitial lung disease: The median time to onset of EGFR-TKI-associated ILD is not well-known, however, the landmark phase 3 trial, FLAURA, reported median time to onset of 106 days (range 9 to 425 days) and a case report identified pulmonary toxicity onset as early as five days [40, 41].